Lucentis ranibizumab regulatory update

The U.K.'s NICE issued a final appraisal determination recommending Lucentis ranibizumab from Novartis to treat macular edema secondary to central retinal vein occlusion (CRVO) and for macular edema

Read the full 285 word article

User Sign In